Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Sonnet BioTherapeutics stock | $1.55
Learn how to easily invest in Sonnet BioTherapeutics stock.
Sonnet BioTherapeutics Holdings, Inc is a biotechnology business based in the US. Sonnet BioTherapeutics shares (SONN) are listed on the NASDAQ and all prices are listed in US Dollars. Sonnet BioTherapeutics employs 9 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Sonnet BioTherapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – SONN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Sonnet BioTherapeutics stock price (NASDAQ: SONN)Use our graph to track the performance of SONN stocks over time.
Sonnet BioTherapeutics shares at a glance
|Latest market close||$1.55|
|52-week range||$1.00 - $4.29|
|50-day moving average||$1.40|
|200-day moving average||$2.04|
|Wall St. target price||$8.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-66.46|
Buy Sonnet BioTherapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Sonnet BioTherapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Sonnet BioTherapeutics price performance over time
|1 week (2021-07-25)||N/A|
|1 month (2021-07-02)||2.65%|
|3 months (2021-05-05)||-17.99%|
|6 months (2021-02-01)||N/A|
|1 year (2020-08-01)||N/A|
|2 years (2019-08-01)||N/A|
|3 years (2018-08-01)||N/A|
|5 years (2016-08-01)||N/A|
Sonnet BioTherapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-356.91%|
|Return on equity TTM||-27822.18%|
|Market capitalisation||$24 million|
TTM: trailing 12 months
Shorting Sonnet BioTherapeutics shares
There are currently 2.1 million Sonnet BioTherapeutics shares held short by investors – that's known as Sonnet BioTherapeutics's "short interest". This figure is 48.7% up from 1.4 million last month.
There are a few different ways that this level of interest in shorting Sonnet BioTherapeutics shares can be evaluated.
Sonnet BioTherapeutics's "short interest ratio" (SIR)
Sonnet BioTherapeutics's "short interest ratio" (SIR) is the quantity of Sonnet BioTherapeutics shares currently shorted divided by the average quantity of Sonnet BioTherapeutics shares traded daily (recently around 808893.10344828). Sonnet BioTherapeutics's SIR currently stands at 2.61. In other words for every 100,000 Sonnet BioTherapeutics shares traded daily on the market, roughly 2610 shares are currently held short.
However Sonnet BioTherapeutics's short interest can also be evaluated against the total number of Sonnet BioTherapeutics shares, or, against the total number of tradable Sonnet BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sonnet BioTherapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Sonnet BioTherapeutics shares in existence, roughly 100 shares are currently held short) or 0.1133% of the tradable shares (for every 100,000 tradable Sonnet BioTherapeutics shares, roughly 113 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sonnet BioTherapeutics.
Find out more about how you can short Sonnet BioTherapeutics stock.
Sonnet BioTherapeutics share dividends
We're not expecting Sonnet BioTherapeutics to pay a dividend over the next 12 months.
Have Sonnet BioTherapeutics's shares ever split?
Sonnet BioTherapeutics's shares were split on a 1:26 basis on 1 April 2020. So if you had owned 26 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sonnet BioTherapeutics shares – just the quantity. However, indirectly, the new 2500% higher share price could have impacted the market appetite for Sonnet BioTherapeutics shares which in turn could have impacted Sonnet BioTherapeutics's share price.
Sonnet BioTherapeutics overview
Sonnet BioTherapeutics Holdings, Inc. , an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neuropathy. The company is also developing SON-081, a low dose IL-6 for the treatment of patients with diabetic peripheral neuropathy and is under phase I trials; SON-1010, a FHAB derived compound, which utilizes a human version of Interleukin-12 (IL-12) is under pre-clinical trial, as well as SON-1210, a bi-specific construct that combines FHAB with IL-12 and human Interleukin-15 for the treatment of solid tumor is under pre-clinical trial. In addition, it develops SON-2014, a bi-specific combination of granulocyte-macrophage colony stimulating factor and Interleukin-18 for the treatment of cancer; and SON-3015, a bi-specific combination of anti-IL6 and anti-tumor growth factor beta for tumor and bone metastases. Sonnet BioTherapeutics Holdings, Inc.
Stocks similar to Sonnet BioTherapeutics
Sonnet BioTherapeutics in the news
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Friday
Frequently asked questionsWhat percentage of Sonnet BioTherapeutics is owned by insiders or institutions?
Currently 8.801% of Sonnet BioTherapeutics shares are held by insiders and 3.437% by institutions. How many people work for Sonnet BioTherapeutics?
Latest data suggests 9 work at Sonnet BioTherapeutics. When does the fiscal year end for Sonnet BioTherapeutics?
Sonnet BioTherapeutics's fiscal year ends in December. Where is Sonnet BioTherapeutics based?
Sonnet BioTherapeutics's address is: 100 Overlook Center, Princeton, NJ, United States, 08540 What is Sonnet BioTherapeutics's ISIN number?
Sonnet BioTherapeutics's international securities identification number is: US83548R1059 What is Sonnet BioTherapeutics's CUSIP number?
Sonnet BioTherapeutics's Committee on Uniform Securities Identification Procedures number is: 15930P206
More guides on Finder
How to buy Chobani stock when it goes public
Everything we know about the Chobani IPO, plus information on how to buy in.
How to buy Stronghold Digital Mining (SDIG) stock when it goes public
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
How to buy ROX Financial LP (ROXA) stock when it goes public
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
Ask an Expert